GlaxoSmithKline Tanzeum available in U.S. pharmacies

News Breaks

July 29, 2014 15:38 EDT GSK GlaxoSmithKline Tanzeum available in U.S. pharmacies
GlaxoSmithKline announced that once-weekly Tanzeum, a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S. The medicine was approved by the FDA on April 15 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

News For GSK From The Last 14 Days

Check below for free stories on GSK the last two weeks.

July 29, 2014 07:40 EDT GSK Court date set for Glaxo investigators arrested in China, WSJ says
Two investigators who were hired by GlaxoSmithKline last year to look into a sex video taken of the drug company’s top China executive, and who were subsequently placed in custody by Chinese authorities on charges of illegally purchasing personal information about Chinese nationals, will stand trial August 8, reported The Wall Street Journal. Reference Link July 28, 2014 10:02 EDT GSK On The Fly: Analyst Downgrade Summary
Today’s noteworthy downgrades include: AcelRx (ACRX) downgraded to Hold from Buy at Canaccord… Anglo American (AAUKY) downgraded to Neutral from Buy at UBS… Aon plc (AON) downgraded to Hold from Buy at Sandler ONeill… Cabot Oil & Gas (COG) downgraded at Oppenheimer… Cisco (CSCO) downgraded to Sector Perform from Outperform at Pacific Crest… Coeur Mining (CDE) downgraded to Market Perform from Outperform at Raymond James… DSW (DSW) downgraded at Sterne Agee… DuPont Fabros (DFT) downgraded to Neutral from Buy at Citigroup… El Paso Electric (EE) downgraded to Hold from Buy at Jefferies… Enphase Energy (ENPH) downgraded to Hold from Buy at Deutsche Bank… GlaxoSmithKline (GSK) downgraded to Neutral from Buy at BofA/Merrill… Horizon Technology (HRZN) downgraded to Hold from Buy at Wunderlich… Lear (LEA) downgraded to Hold from Buy at Deutsche Bank… Life Time Fitness (LTM) downgraded at Wedbush… Monster Beverage (MNST) downgraded to Neutral from Buy at UBS… NRG Energy (NRG) downgraded to Buy from Conviction Buy at Goldman… PG&E (PCG) downgraded to Sell from Neutral at Goldman… Pfizer (PFE) downgraded at BMO Capital… Post Properties (PPS) downgraded to Neutral from Buy at Citigroup… Publicis (PUBGY) downgraded to Sell from Neutral at Citigroup… Selmer Scientific (SMLR) downgraded to Hold from Buy at Aegis… TransCanada (TRP) downgraded to Neutral from Outperform at Credit Suisse… Travelers (TRV) downgraded to Hold from Buy at Sandler O’Neill… Zurich Insurance (ZURVY) downgraded to Underperform from Market Perform at Bernstein. 08:09 EDT GSK GlaxoSmithKline downgraded to Neutral from Buy at BofA/Merrill 06:22 EDT GSK GlaxoSmithKline could eventually spin off consumer healthcare business, FT says
GlaxoSmithKline CEO Andrew Witty is considering the possibility of the company being broken up in the future, suggesting that the consumer healthcare business could be spun off if a time comes when it is more valuable as an independent company, the Financial Times reports. Witty says there are no such plans in the near term. Reference Link July 24, 2014 13:29 EDT GSK GlaxoSmithKline facing bribery allegations in Syria, Reuters says
Subscribe for More Information 12:41 EDT GSK GlaxoSmithKline reports FDA approves Flonase for OTC sales in U.S.
Subscribe for More Information 11:45 EDT GSK GlaxoSmithKline downgraded to Sell from Neutral at UBS
Subscribe for More Information 06:13 EDT GSK GlaxoSmithKline’s malaria vaccine candidate accepted for EU regulatory review
Subscribe for More Information July 23, 2014 09:33 EDT GSK GlaxoSmithKline reports record Promacta/Revolade Q2 revenue of $92M
Subscribe for More Information 09:17 EDT GSK On The Fly: Pre-market Movers
Subscribe for More Information 07:19 EDT GSK Genmab reports Q2 Arzerra net sales GBP 12.8M
Subscribe for More Information 07:12 EDT GSK GlaxoSmithKline lowers 2014 core EPS outlook to ‘similar’ to 2013
GSK now expects 2014 core EPS to be “broadly similar” to 2013 versus previous expectations of 4%-8% growth. It added, “Given impact of recent sustained strength of Sterling on free cash flow, share repurchases over balance of 2014 likely to be immaterial.” 07:09 EDT GSK GlaxoSmithKline reports Q2 core EPS down 12% to 19.1p
Subscribe for More Information 07:09 EDT GSK Mylan wins restraining order against Apotex for generic version of GSK’s Paxil
Subscribe for More Information July 22, 2014 09:55 EDT GSK Lupin, private equity funds weigh bids for GSK’s older drugs, Reuters reports
Subscribe for More Information July 21, 2014 07:11 EDT GSK International Society of DNA Vaccines to hold a conference
Subscribe for More Information July 17, 2014 07:18 EDT GSK Mylan wins motion to enjoin GlaxoSmithKline from production of generic product
Subscribe for More Information 06:23 EDT GSK GlaxoSmithKline admits to bribing Chinese officials in 2001, FT reports
Subscribe for More Information July 16, 2014 07:14 EDT GSK Isis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx. 05:38 EDT GSK GSK, Theravance initiate Phase III IMPACT study
GlaxoSmithKline (GSK) and Theravance (THRX) announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease, or COPD. IMPACT is the first pivotal phase III study in a programme to evaluate a once-daily closed triple combination treatment of an inhaled corticosteroid, or ICS; a long-acting muscarinic antagonist, or LAMA; and a long-acting beta2-adrenergic agonist, or LABA, in patients with COPD. The IMPACT study will enrol approximately 10,000 patients and assess whether the combination of FF, or fluticasone furoate, an ICS, UMEC, or umeclidinium, a LAMA, and VI, or vilanterol, a LABA, all delivered in GSK’s Ellipta inhaler, can reduce the annual rate of moderate and severe exacerbations compared with two approved once daily COPD treatments, Relvar/Breo Ellipta, FF/VI, which is an ICS/LABA combination, and Anoro Ellipta, UMEC/VI, which is a LAMA/LABA combination.